Abstract
Background
Effective oral delivery of drugs remains a major challenge given their possible undesirable physicochemical properties, physicochemical factors, and the physiological conditions of the gastrointestinal (GI) tract. Continuous efforts have been made to overcome these issues by improving the intestinal permeability and oral bioavailability of drugs. Recently, the strategy to improve intestinal permeability has shifted towards targeting drugs to intestinal membrane transporters.
Area covered
In this review, the usefulness of various solute carrier (SLC) and ATP (adenosine triphosphate)-binding cassette (ABC) transporters that are widely expressed in the intestinal epithelia and their impact on increasing the membrane permeability and oral bioavailability of drugs are discussed.
Expert opinion
Targeting intestinal membrane transporters has emerged as a promising avenue to increase the oral absorption of drugs. Recently, several approaches that target intestinal membrane transporters have resulted in significant improvements in oral bioavailability, such as the use of absorption enhancers or excipients, modification of a drug’s physicochemical properties, and/or the development of novel drug delivery vehicles that enhance drug influx and inhibit efflux. Additionally, efforts have been made to elucidate the role of dual-transporter targeting in drug delivery. Therefore, implementation of transporter-mediated drug-delivery strategies may be a promising approach to increase oral bioavailability.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abrantes CG, Duarte D, Reis CP (2016) An overview of pharmaceutical excipients: safe or not safe? J Pharm Sci 105(7):2019–2026. https://doi.org/10.1016/j.xphs.2016.03.019
Agarwal S, Boddu SHS, Jain R et al (2008) Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor. Int J Pharm 359(1):7–14. https://doi.org/10.1016/j.ijpharm.2008.03.031
Al-Hilal TA, Park J, Alam F et al (2014) Oligomeric bile acid-mediated oral delivery of low molecular weight heparin. J Control Release 175:17–24. https://doi.org/10.1016/j.jconrel.2013.12.001
Athukuri BL, Neerati P (2017) Enhanced oral bioavailability of domperidone with piperine in male wistar rats: involvement of CYP3A1 and P-gp inhibition. J Pharm Pharm Sci 20:28–37. https://doi.org/10.18433/J3MK72
Austin Doyle L, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22(47):7340–7358. https://doi.org/10.1038/sj.onc.1206938
Balakrishnan A, Polli JE (2006) Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol Pharm 3(3):223–230. https://doi.org/10.1021/mp060022d
Borst P, de Wolf C, van de Wetering K (2007) Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch 453(5):661–673. https://doi.org/10.1007/s00424-006-0054-9
Breedveld P, Beijnen JH, Schellens JH (2006) Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharm Sci 27(1):17–24. https://doi.org/10.1016/j.tips.2005.11.009
Brodin B, Nielsen CU, Steffansen B et al (2002) Transport of peptidomimetic drugs by the intestinal Di/tri-peptide transporter, PepT1. Pharm Toxicol 90(6):285–296. https://doi.org/10.1034/j.1600-0773.2002.900601.x
Bu X, Zhu T, Ma Y et al (2015) Co-administration with cell penetrating peptide enhances the oral bioavailability of docetaxel-loaded nanoparticles. Drug Dev Ind Pharm 41(5):764–771. https://doi.org/10.3109/03639045.2014.902465
Cai Z, Huang J, Luo H et al (2013) Role of glucose transporters in the intestinal absorption of gastrodin, a highly water-soluble drug with good oral bioavailability. J Drug Target 21(6):574–580. https://doi.org/10.3109/1061186X.2013.778263
Cao F, Gao Y, Wang M et al (2013) Propylene glycol-linked amino acid/dipeptide diester prodrugs of oleanolic acid for PepT1-mediated transport: synthesis, intestinal permeability, and pharmacokinetics. Mol Pharm 10(4):1378–1387. https://doi.org/10.1021/mp300647m
Cao J, Chen X, Liang J et al (2007) Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of glycyrrhiza glabra. Drug Metab Dispos 35(4):539–553. https://doi.org/10.1124/dmd.106.010801
Choi JS, Jo BW (2004) Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int J Pharm 280(1–2):221–227. https://doi.org/10.1016/j.ijpharm.2004.05.014
Constantinides PP, Wasan KM (2007) Lipid formulation strategies for enhancing intestinal transport and absorption of P-Glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci 96(2):235–248. https://doi.org/10.1002/jps.20780
Cristofoletti R, Chiann C, Dressman JB et al (2013) A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies. J Pharm Sci 102(9):3136–3144. https://doi.org/10.1002/jps.23515
Dawson PA (2011) Role of the intestinal bile acid transporters in bile acid and drug disposition. Handb Exp Pharm. https://doi.org/10.1007/978-3-642-14541-4_4
Dawson PA, Lan T, Rao A (2009) Bile acid transporters. J Lipid Res 50(12):2340–2357. https://doi.org/10.1194/jlr.R900012-JLR200
Deng F, Bae YH (2020) Bile acid transporter-mediated oral drug delivery. J Control Release 327:100–116. https://doi.org/10.1016/j.jconrel.2020.07.034
Dian L, Yu E, Chen X et al (2014) Enhancing oral bioavailability of quercetin using novel soluplus polymeric micelles. Nanoscale Res Lett 9(1):1–11. https://doi.org/10.1186/1556-276X-9-684
Diestra JE, Scheffer GL, Catala I et al (2002) Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 198(2):213–219. https://doi.org/10.1002/path.1203
Dietrich CG, de Waart DR, Ottenhoff R et al (2001) Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol Pharmacol 59(5):974–980. https://doi.org/10.1124/mol.59.5.974
Dietrich CG, Geier A, Oude Elferink RP (2003) ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52(12):1788–1795. https://doi.org/10.1136/gut.52.12.1788
Dohse M, Scharenberg C, Shukla S et al (2010) Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 38(8):1371–1380. https://doi.org/10.1124/dmd.109.031302
Drozdzik M, Czekawy I, Oswald S et al (2020) Intestinal drug transporters in pathological states: an overview. Pharm Rep 72(5):1173–1194. https://doi.org/10.1007/s43440-020-00139-6
Du Y, Tian C, Wang M et al (2018) Dipeptide-modified nanoparticles to facilitate oral docetaxel delivery: new insights into PepT1-mediated targeting strategy. Drug Deliv 25(1):1403–1413. https://doi.org/10.1080/10717544.2018.1480675
Estudante M, Morais JG, Soveral G et al (2013) Intestinal drug transporters: an overview. Adv Drug Deliv Rev 65(10):1340–1356. https://doi.org/10.1016/j.addr.2012.09.042
Ezra A, Hoffman A, Breuer E et al (2000) A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem 43(20):3641–3652. https://doi.org/10.1021/jm980645y
Fan W, Xia D, Zhu Q et al (2018) Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials 151:13–23. https://doi.org/10.1016/j.biomaterials.2017.10.022
Feng SS, Mei L, Anitha P et al (2009) Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of docetaxel. Biomaterials 30(19):3297–3306. https://doi.org/10.1016/j.biomaterials.2009.02.045
Foley DW, Pathak RB, Phillips TR et al (2018) Thiodipeptides targeting the intestinal oligopeptide transporter as a general approach to improving oral drug delivery. Eur J Med Chem 156:180–189. https://doi.org/10.1016/j.ejmech.2018.06.064
George AM, Jones PM (2012) Perspectives on the structure-function of ABC transporters: the switch and constant contact models. Prog Biophys Mol Biol 109(3):95–107. https://doi.org/10.1016/j.pbiomolbio.2012.06.003
Gilzad Kohan H, Kaur K, Jamali F (2015) Synthesis and characterization of a new peptide prodrug of glucosamine with enhanced gut permeability. PLoS ONE 10(5):e0126786. https://doi.org/10.1371/journal.pone.0126786
Gonzalez DE, Covitz KM, Sadee W et al (1998) An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res 58(3):519–525
Gourdon B, Chemin C, Moreau A et al (2017) Functionalized PLA-PEG nanoparticles targeting intestinal transporter PepT1 for oral delivery of acyclovir. Int J Pharm 529(1–2):357–370. https://doi.org/10.1016/j.ijpharm.2017.07.024
Gourdon B, Chemin C, Moreau A et al (2018) Influence of PLA-PEG nanoparticles manufacturing process on intestinal transporter PepT1 targeting and oxytocin transport. Eur J Pharm Biopharm 129:122–133. https://doi.org/10.1016/j.ejpb.2018.05.022
Guan P, Lu Y, Qi J et al (2011) Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomed 6:965–974. https://doi.org/10.2147/IJN.S19259
Guo M, Yu S, Huang Y et al (2020) A novel cascade strategy using a nanonized targeted prodrug for enhanced oral delivery efficiency. Int J Pharm 587:119638–119648. https://doi.org/10.1016/j.ijpharm.2020.119638
Gupta D, Varghese Gupta S, Dahan A et al (2013) Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol Pharm 10(2):512–522. https://doi.org/10.1021/mp300564v
Han TK, Everett RS, Proctor WR et al (2013) Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes. Mol Pharmacol 84(2):182–189. https://doi.org/10.1124/mol.112.084517
Hanke U, May K, Rozehnal V et al (2010) Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2). Eur J Pharm Biopharm 76(2):260–268. https://doi.org/10.1016/j.ejpb.2010.06.008
Hashimoto T, Nomoto M, Komatsu K et al (2000) Improvement of intestinal absorption of peptides: adsorption of B1-Phe monoglucosylated insulin to rat intestinal brush-border membrane vesicles. Eur J Pharm Biopharm 50(2):197–204. https://doi.org/10.1016/S0939-6411(00)00082-5
Hatanaka T, Haramura M, Fei YJ et al (2004) Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther 308(3):1138–1147. https://doi.org/10.1124/jpet.103.057109
He C, Jin Y, Deng Y et al (2020) Efficient oral delivery of poorly water-soluble drugs using carnitine/organic cation transporter 2-mediated polymeric micelles. ACS Biomater Sci Eng 6(4):2146–2158. https://doi.org/10.1021/acsbiomaterials.0c00020
He L, Vasiliou K, Nebert DW (2009) Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics 3(2):195. https://doi.org/10.1186/1479-7364-3-2-195
Hirohashi T, Suzuki H, Takikawa H et al (2000) ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 275(4):2905–2910. https://doi.org/10.1074/jbc.275.4.2905
Hoosain FG, Choonara YE, Tomar LK et al (2015) Bypassing P-glycoprotein drug efflux mechanisms: possible applications in pharmacoresistant schizophrenia therapy. Biomed Res Int 2015:1–21. https://doi.org/10.1155/2015/484963
Hu M, Zhang J, Ding R et al (2017) Improved oral bioavailability and therapeutic efficacy of dabigatran etexilate via Soluplus-TPGS binary mixed micelles system. Drug Dev Ind Pharm 43(4):687–697. https://doi.org/10.1080/03639045.2016.1278015
Hu Z, Nizzero S, Goel S et al (2020) Molecular targeting of FATP4 transporter for oral delivery of therapeutic peptide. Sci Adv 6(14):eaba0145. https://doi.org/10.1126/sciadv.aba0145
Inoue M, Terada T, Okuda M et al (2005) Regulation of human peptide transporter 1 (PEPT1) in gastric cancer cells by anticancer drugs. Cancer Lett 230(1):72–80. https://doi.org/10.1016/j.canlet.2004.12.023
International Transporter C, Giacomini KM, Huang SM et al (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215–236. https://doi.org/10.1038/nrd3028
Ito K, Hikida A, Kawai S et al (2013) Analysing the substrate multispecificity of a proton-coupled oligopeptide transporter using a dipeptide library. Nat Commun 4(1):2502. https://doi.org/10.1038/ncomms3502
Ito K, Suzuki H, Horie T et al (2005) Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 22(10):1559–1577. https://doi.org/10.1007/s11095-005-6810-2
Jeon O-C, Hwang SR, Al-Hilal TA et al (2013) Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates. Pharm Res 30(4):959–967. https://doi.org/10.1007/s11095-012-0932-0
Jeon OC, Seo DH, Kim HS et al (2016) Oral delivery of zoledronic acid by non-covalent conjugation with lysine-deoxycholic acid: in vitro characterization and in vivo anti-osteoporotic efficacy in ovariectomized rats. Eur J Pharm Sci 82:1–10. https://doi.org/10.1016/j.ejps.2015.11.004
Jha SK, Chung JY, Pangeni R et al (2020) Enhanced antitumor efficacy of bile acid-lipid complex-anchored docetaxel nanoemulsion via oral metronomic scheduling. J Control Release 328:368–394. https://doi.org/10.1016/j.jconrel.2020.08.067
Jin Y, Liu Q, Zhou C et al (2019) Intestinal oligopeptide transporter PepT1-targeted polymeric micelles for further enhancing the oral absorption of water-insoluble agents. Nanoscale 11(44):21433–21448. https://doi.org/10.1039/C9NR07029J
Jonker JW, Smit JW, Brinkhuis RF et al (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92(20):1651–1656. https://doi.org/10.1093/jnci/92.20.1651
Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455(1):152–162. https://doi.org/10.1016/0005-2736(76)90160-7
Kalepu S, Manthina M, Padavala V (2013) Oral lipid-based drug delivery systems – an overview. Acta Pharm Sin B 3(6):361–372. https://doi.org/10.1016/j.apsb.2013.10.001
Keiser M, Kaltheuner L, Wildberg C et al (2017) The organic anion-transporting peptide 2B1 Is localized in the basolateral membrane of the human jejunum and Caco-2 monolayers. J Pharm Sci 106(9):2657–2663. https://doi.org/10.1016/j.xphs.2017.04.001
Khandavilli S, Panchagnula R (2007) Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J Invest Dermatol 127(1):154–162. https://doi.org/10.1038/sj.jid.5700485
Kool M, de Haas M, Scheffer GL et al (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57(16):3537–3547
Kou L, Yao Q, Sivaprakasam S et al (2017a) Dual targeting of l-carnitine-conjugated nanoparticles to OCTN2 and ATB(0,+) to deliver chemotherapeutic agents for colon cancer therapy. Drug Deliv 24(1):1338–1349. https://doi.org/10.1080/10717544.2017.1377316
Kou L, Yao Q, Sun M et al (2017b) Cotransporting ion is a trigger for cellular endocytosis of transporter-targeting nanoparticles: a case study of high-efficiency SLC22A5 (OCTN2)-mediated carnitine-conjugated nanoparticles for oral delivery of therapeutic drugs. Adv Healthc Mater 6(17):1700165. https://doi.org/10.1002/adhm.201700165
Lal R, Sukbuntherng J, Luo W et al (2010) Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharm 69(5):498–507. https://doi.org/10.1111/j.1365-2125.2010.03616.x
Li L, Yi T, Lam CW (2013) Interactions between human multidrug resistance related protein (MRP2; ABCC2) and excipients commonly used in self-emulsifying drug delivery systems (SEDDS). Int J Pharm 447(1):192–198. https://doi.org/10.1016/j.ijpharm.2013.02.016
Lin L, Yee SW, Kim RB et al (2015) SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov 14(8):543–560. https://doi.org/10.1038/nrd4626
Longfa K, Bhutia YD, Yao Q et al (2018) Transporter-guided delivery of nanoparticles to improve drug permeation across cellular barriers and drug exposure to selective cell types. Front Pharmacol. https://doi.org/10.3389/fphar.2018.00027
Lozano E, Herraez E, Briz O et al (2013) Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. Biomed Res Int 2013:692071. https://doi.org/10.1155/2013/692071
Ma J, Wang Q, Huang Z et al (2017) Glycosylated platinum(IV) complexes as substrates for glucose transporters (GLUTs) and organic cation transporters (OCTs) exhibited cancer targeting and human serum albumin binding properties for drug delivery. J Med Chem 60(13):5736–5748. https://doi.org/10.1021/acs.jmedchem.7b00433
Maher S, Brayden DJ, Casettari L et al (2019) Application of permeation enhancers in oral delivery of macromolecules: an update. Pharmaceutics. https://doi.org/10.3390/pharmaceutics11010041
Maher S, Mrsny RJ, Brayden DJ (2016) Intestinal permeation enhancers for oral peptide delivery. Adv Drug Deliv Rev 106:277–319. https://doi.org/10.1016/j.addr.2016.06.005
Mao Q, Unadkat JD (2015) Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport–an update. AAPS J 17(1):65–82. https://doi.org/10.1208/s12248-014-9668-6
McKinlay CJ, Waymouth RM, Wender PA (2016) Cell-penetrating, guanidinium-rich oligophosphoesters: effective and versatile molecular transporters for drug and probe delivery. J Am Chem Soc 138(10):3510–3517. https://doi.org/10.1021/jacs.5b13452
Meier Y, Eloranta JJ, Darimont J et al (2007) Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos 35(4):590–594. https://doi.org/10.1124/dmd.106.013342
Merigo F, Brandolese A, Facchin S et al (2018) Glucose transporter expression in the human colon. World J Gastroenterol 24(7):775–793. https://doi.org/10.3748/wjg.v24.i7.775
Mooij MG, Nies AT, Knibbe CAJ et al (2016) Development of human membrane transporters: drug disposition and pharmacogenetics. Clin Pharmacokinet 55(5):507–524. https://doi.org/10.1007/s40262-015-0328-5
Moradi SV, Hussein WM, Varamini P et al (2016) Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides. Chem Sci 7(4):2492–2500. https://doi.org/10.1039/C5SC04392A
Mudie DM, Amidon GL, Amidon GE (2010) Physiological parameters for oral delivery and in vitro testing. Mol Pharm 7(5):1388–1405. https://doi.org/10.1021/mp100149j
Muller J, Lips KS, Metzner L et al (2005) Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 70(12):1851–1860. https://doi.org/10.1016/j.bcp.2005.09.011
Murakami T, Takano M (2008) Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 4(7):923–939. https://doi.org/10.1517/17425255.4.7.923
Nakanishi T (2007) Drug transporters as targets for cancer chemotherapy. Cancer Genomics Proteomics 4(3):241–254
Oswald S (2019) Organic Anion Transporting Polypeptide (OATP) transporter expression, localization and function in the human intestine. Pharmacol Ther 195:39–53. https://doi.org/10.1016/j.pharmthera.2018.10.007
Pangeni R, Choi JU, Panthi VK et al (2018) Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect. Int J Nanomed 13:3329–3351. https://doi.org/10.2147/IJN.S167958
Pangeni R, Choi SW, Jeon OC et al (2016) Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation. Int J Nanomed 11:6379–6399. https://doi.org/10.2147/IJN.S121114
Pangeni R, Jha SK, Maharjan R et al (2019) Intestinal transport mechanism and in vivo anticancer efficacy of a solid oral formulation incorporating an ion-pairing complex of pemetrexed with deoxycholic acid derivative. Int J Nanomed 14:6339–6356. https://doi.org/10.2147/IJN.S209722
Pochini L, Scalise M, Galluccio M et al (2013) OCTN cation transporters in health and disease: role as drug targets and assay development. J Biomol Screen 18(8):851–867. https://doi.org/10.1177/1087057113493006
Raju A, Muthu MS, Feng SS (2013) Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Expert Opin Drug Deliv 10(6):747–760. https://doi.org/10.1517/17425247.2013.777425
Rehman S, Nabi B, Fazil M et al (2017) Role of P-glycoprotein inhibitors in the bioavailability enhancement of solid dispersion of darunavir. Biomed Res Int 2017:8274927. https://doi.org/10.1155/2017/8274927
Rubio-Aliaga I, Daniel H (2008) Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica 38(7–8):1022–1042. https://doi.org/10.1080/00498250701875254
Ruiz-Picazo A, Gonzalez-Alvarez M, Gonzalez-Alvarez I et al (2020) Effect of common excipients on intestinal drug absorption in wistar rats. Mol Pharm 17(7):2310–2318. https://doi.org/10.1021/acs.molpharmaceut.0c00023
Samstein RM, Perica K, Balderrama F et al (2008) The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles. Biomaterials 29(6):703–708. https://doi.org/10.1016/j.biomaterials.2007.10.026
Sawangrat K, Yamashita S, Tanaka A et al (2019) Modulation of intestinal transport and absorption of topotecan, a BCRP substrate, by various pharmaceutical excipients and their inhibitory mechanisms of BCRP transporter. J Pharm Sci 108(3):1315–1325. https://doi.org/10.1016/j.xphs.2018.10.043
Shan W, Zhu X, Tao W et al (2016) Enhanced oral delivery of protein drugs using zwitterion-functionalized nanoparticles to overcome both the diffusion and absorption barriers. ACS Appl Mater Interfaces 8(38):25444–25453. https://doi.org/10.1021/acsami.6b08183
Shen Q, Wang Y, Zhang Y (2011) Improvement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancer. Int J Nanomed 6:1237–1243. https://doi.org/10.2147/IJN.S20903
Shirasaka Y, Suzuki K, Nakanishi T et al (2010) Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide. Pharm Res 27(10):2141–2149. https://doi.org/10.1007/s11095-010-0216-5
Sievanen E (2007) Exploitation of bile acid transport systems in prodrug design. Molecules 12(8):1859–1889. https://doi.org/10.3390/12081859
Singh MS, Juvale K, Wiese M et al (2015) Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation. Eur J Pharm Sci 77:1–8. https://doi.org/10.1016/j.ejps.2015.04.027
St-Pierre MV, Serrano MA, Macias RIR et al (2000) Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 279(4):R1495–R1503. https://doi.org/10.1152/ajpregu.2000.279.4.R1495
Stewart CF, Leggas M, Schuetz JD et al (2004) Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64(20):7491–7499. https://doi.org/10.1158/0008-5472.CAN-04-0096
Sun J, Dahan A, Amidon GL (2010) Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach. J Med Chem 53(2):624–632. https://doi.org/10.1021/jm9011559
Sun L, Le Z, He S et al (2020) Flash fabrication of orally targeted nanocomplexes for improved transport of salmon calcitonin across the intestine. Mol Pharm 17(3):757–768. https://doi.org/10.1021/acs.molpharmaceut.9b00827
Sun Y, Gan W, Lei M et al (2018) PEPT1-mediated prodrug strategy for oral delivery of peramivir. Asian J Pharm Sci 13(6):555–565. https://doi.org/10.1016/j.ajps.2018.05.008
Takano M, Yumoto R, Murakami T (2006) Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 109(1):137–161. https://doi.org/10.1016/j.pharmthera.2005.06.005
Tamminen J, Kolehmainen E (2001) Bile acids as building blocks of supramolecular hosts. Molecules 6(1):21–46. https://doi.org/10.3390/60100021
Tao W, Zhao D, Sun M et al (2017) Enzymatic activation of double-targeted 5’-O-L-valyl-decitabine prodrug by biphenyl hydrolase-like protein and its molecular design basis. Drug Deliv Transl Res 7(2):304–311. https://doi.org/10.1007/s13346-016-0356-1
Thakkar H, Desai J (2015) Influence of excipients on drug absorption via modulation of intestinal transporters activity. Asian J Pharm 9:69
Thanki K, Gangwal RP, Sangamwar AT et al (2013) Oral delivery of anticancer drugs: challenges and opportunities. J Control Release 170(1):15–40. https://doi.org/10.1016/j.jconrel.2013.04.020
Tian C, Asghar S, Wu Y et al (2017) Improving intestinal absorption and oral bioavailability of curcumin via taurocholic acid-modified nanostructured lipid carriers. Int. J. Nanomed 12:7897. https://doi.org/10.2147/IJN.S145988
Tolle-Sander S, Lentz KA, Maeda DY et al (2004) Increased acyclovir oral bioavailability via a bile acid conjugate. Mol Pharm 1(1):40–48. https://doi.org/10.1021/mp034010t
Torres-Lugo M, Santos-Roman N, Mendez J, et al (2007). Poly(ethylene glycol) hydrogels as possible multidrug resistance associated protein (MRP) inhibitors. Paper presented at the 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 22–26 Aug 2007
Tsume Y, Hilfinger JM, Amidon GL (2008) Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: Increased transporter affinity and metabolic stability. Mol Pharm 5(5):717–727. https://doi.org/10.1021/mp800008c
Tuvia S, Pelled D, Marom K et al (2014) A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm Res 31(8):2010–2021. https://doi.org/10.1007/s11095-014-1303-9
Varma MV, Ambler CM, Ullah M et al (2010) Targeting intestinal transporters for optimizing oral drug absorption. Curr Drug Metab 11(9):730–742. https://doi.org/10.2174/138920010794328850
Varma MV, Rotter CJ, Chupka J et al (2011) pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm 8(4):1303–1313. https://doi.org/10.1021/mp200103h
Wang D-S, Jonker JW, Kato Y et al (2002) Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302(2):510. https://doi.org/10.1124/jpet.102.034140
Wang G, Chen H, Zhao D et al (2017) Combination of l-carnitine with lipophilic linkage-donating gemcitabine derivatives as intestinal novel organic cation transporter 2-targeting oral prodrugs. J Med Chem 60(6):2552–2561. https://doi.org/10.1021/acs.jmedchem.7b00049
Wang J, Wang L, Li Y et al (2018) Apically targeted oral micelles exhibit highly efficient intestinal uptake and oral absorption. Int J Nanomed 13:7997–8012. https://doi.org/10.2147/IJN.S183796
Wang Y, Wang G, Chen H et al (2020) A facile di-acid mono-amidation strategy to prepare cyclization-activating mono-carboxylate transporter 1-targeting gemcitabine prodrugs for enhanced oral delivery. Int J Pharm 573:118718. https://doi.org/10.1016/j.ijpharm.2019.118718
Whitehead K, Karr N, Mitragotri S (2008) Safe and effective permeation enhancers for oral drug delivery. Pharm Res 25(8):1782–1788. https://doi.org/10.1007/s11095-007-9488-9
Wu L, Liu M, Shan W et al (2017) Bioinspired butyrate-functionalized nanovehicles for targeted oral delivery of biomacromolecular drugs. J Control Release 262:273–283. https://doi.org/10.1016/j.jconrel.2017.07.045
Xia D, He Y, Li Q et al (2018) Transport mechanism of lipid covered saquinavir pure drug nanoparticles in intestinal epithelium. J Control Release 269:159–170. https://doi.org/10.1016/j.jconrel.2017.11.012
Xiao L, Yi T, Chen M et al (2016) A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: activation of MRP3 with concurrent inhibition of MRP2 and BCRP. Eur J Pharm Sci 93:456–467. https://doi.org/10.1016/j.ejps.2016.08.054
Xie J, Zhu XY, Liu LM et al (2018) Solute carrier transporters: potential targets for digestive system neoplasms. Cancer Manag Res 10:153–166. https://doi.org/10.2147/CMAR.S152951
Xin Hua Z (1994) Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J Control Release 29(3):239–252. https://doi.org/10.1016/0168-3659(94)90071-X
Xu Y, Shrestha N, Preat V et al (2020) Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems. J Control Release 322:486–508. https://doi.org/10.1016/j.jconrel.2020.04.006
Yamagata T, Kusuhara H, Morishita M et al (2007) Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metab Dispos 35(7):1142–1148. https://doi.org/10.1124/dmd.106.014217
Yu J, Zhou Z, Tay-Sontheimer J et al (2017) Intestinal drug interactions mediated by OATPs: a systematic review of preclinical and clinical findings. J Pharm Sci 106(9):2312–2325. https://doi.org/10.1016/j.xphs.2017.04.004
Zhang D, Li D, Shang L et al (2016) Transporter-targeted cholic acid-cytarabine conjugates for improved oral absorption. Int J Pharm 511(1):161–169. https://doi.org/10.1016/j.ijpharm.2016.06.139
Zou L, Pottel J, Khuri N et al (2020) Interactions of oral molecular excipients with breast cancer resistance protein. BCRP Mol Pharm 17(3):748–756. https://doi.org/10.1021/acs.molpharmaceut.9b00658
Acknowledgements
This research was supported by the Basic Research Program through the National Research Foundation of Korea (NRF), funded by the Korean Government Ministry of Science and ICT (MSIT; Grant No. NRF-2020R1F1A1069889). We greatly appreciated using the Convergence Research Laboratory (established by the MNU Innovation Support Project in 2020) to conduct this research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Research involving human and animal rights
This study did not involve any experiments on human or animal subjects.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Pangeni, R., Kang, S., Jha, S.K. et al. Intestinal membrane transporter-mediated approaches to improve oral drug delivery. J. Pharm. Investig. 51, 137–158 (2021). https://doi.org/10.1007/s40005-021-00515-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40005-021-00515-1